Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein Rev

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 7, 2009, Pages 2816-2823

  Svicher, Valentina ^a   Alteri, Claudia ^a   D'Arrigo, Roberta ^b   Laganà, Alessandro ^c   Trignetti, Maria ^a   Lo Caputo, Sergio ^d   Callegaro, Anna Paola ^e   Maggiolo, Franco ^e   Mazzotta, Francesco ^d   Ferro, Alfredo ^c   Dimonte, Salvatore ^a   Aquaro, Stefano ^f   Di Perri, Giovanni ^g   Bonora, Stefano ^g   Tommasi, Chiara ^b   Trotta, Maria Paola ^b   Narciso, Pasquale ^b   Antinori, Andrea ^b   Perno, Carlo Federico ^a,b   Ceccherini Silberstein, Francesca ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d Hospital Santa Maria Annunziata   (Italy)

^e OSPEDALI RIUNITI   (Italy)

^f UNIVERSITY OF CALABRIA   (Italy)

^g UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE; GLYCOPROTEIN GP 41; MESSENGER RNA; MUTANT PROTEIN; PROTEINASE INHIBITOR; REV PROTEIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS ENVELOPE PROTEIN;

ADULT; ARTICLE; BASE PAIRING; BINDING SITE; CD4 LYMPHOCYTE COUNT; CODON; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA RESPONSIVE ELEMENT; EXON; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIFE CYCLE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; TREATMENT FAILURE; VIREMIA; VIRUS GENOME; VIRUS MUTATION; VIRUS RESISTANCE;

ADULT; BASE SEQUENCE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; GENES, ENV; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEIC ACID CONFORMATION; PEPTIDE FRAGMENTS; REV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIREMIA;

EID: 67649975605     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01067-08     Document Type: Article

References (41)

1. Aquaro, S., R. D'Arrigo, V. Svicher, G. D. Perri, S. L. Caputo, U. Visco-Comandini, M. Santoro, A. Bertoli, F. Mazzotta, S. Bonora, V. Tozzi, R. Bellagamba, M. Zaccarelli, P. Narciso, A. Antinori, and C. F. Perno. 2006. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J. Antimicrob. Chemother. 58:714-722.
2. Benjamini, Y., and Y. Hochberg. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57:289-300.
3. Demart, S., F. Ceccherini-Silberstein, S. Schlicht, S. Walcher, H. Wolff, M. Neumann, V. Erfle, and R. Brack-Werner. 2003. Analysis of nuclear targeting activities of transport signals in the human immunodeficiency virus Rev protein. Exp. Cell. Res. 291:484-501.
4. Edgcomb, S. P., A. Aschrafi, E. Kompfner, J. R. Williamson, L. Gerace, and M. Hennig. 2008. Protein structure and oligomerization are important for the formation of export-competent HIV-1 Rev-RRE complexes. Protein Sci. 17:420-430.
5. Freed, E. O., and M. A. Martin. 2001. HIVs and their replication, p. 1971-2041. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 4th ed., vol. II. Lippincott Williams & Wilkins, Philadelphia, PA.
6. Greenberg, M., N. Cammack, M. Salgo, and L. Smiley. 2004. HIV fusion and its inhibition in antiretroviral therapy. Rev. Med. Virol. 14:321-337.
7. Heaphy, S., C. Dingwall, I. Ernberg, M. J. Gait, S. M. Green, J. Karn, A. D. Lowe, M. Singh, and M. A. Skinner. 1990. HIV-1 regulator of virion expression (Rev) protein binds to an RNA stem-loop structure located within the Rev response element region. Cell 60:685-693.
8. Henderson, B. R., and P. Percipalle. 1997. Interactions between HIV Rev. and nuclear import and export factors: the Rev nuclear localisation signal mediates specific binding to human importin-beta. J. Mol. Biol. 274:693-707.
9. Hofacker I. L. 2003. Vienna RNA secondary structure server. Nucleic Acids Res. 13:3429-3431.
10. Holland, S. M., N. Ahmad, R. K. Maitra, P. Wingfield, and S. Venkatesan. 1990. Human immunodeficiency virus rev protein recognizes a target sequence in rev-responsive element RNA within the context of RNA secondary structure. J. Virol. 64:5966-5975.
11. Hope, T. J., B. L. Bond, D. McDonald, N. P. Klein, and T. G. Parslow. 1991. Effector domains of human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type I Rex are functionally interchangeable and share an essential peptide motif. J. Virol. 65:6001-6007.
12. Huang, X. J., T. J. Hope, B. L. Bond, D. McDonald, K. Grahl, and T. G Parslow. 1991. Minimal Rev-response element for type 1 human immunodeficiency virus. J. Virol. 65:2131-2134.
13. Iversen, A. K., E. G. Shpaer, A. G. Rodrigo, M. S. Hirsch, B. D. Walker, H. W. Sheppard, T. C. Merigan, and J. I. Mullins. 1995. Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual. J. Virol. 69:5743-5753.
14. Jain, C., and J. G. Belasco. 2001. Structural model for the cooperative assembly of HIV-1 Rev multimers on the RRE as deduced from analysis of assembly-defective mutants. Mol. Cell 7:603-614.
15. Johnson, V. A., F. Brun-Vezinet, B. Clotet, H. F. Gunthard, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, and D. D. Richman. 2008. Update of the drug resistance mutations in HIV-1: spring 2008. Top. HIV Med. 16:62-68.
16. Kern, A. D., and F. A. Kondrashov. 2004. Mechanisms and convergence of compensatory evolution in mammalian mitochondrial tRNAs. Nat. Gen. 36:1207-1212.
17. Kirby, D. A., S. V. Muse, and W. Stephan. 1995. Maintenance of pre-messenger-RNA secondary structure by epistatic selection. Proc. Nat. Acad. Sci. USA 92:9047-9051.
18. Kjems, J., M. Brown, D. D. Chang, and P. A. Sharp. 1991. Structural analysis of the interaction between the human immunodeficiency virus Rev protein and the Rev response element. Proc. Natl. Acad. Sci. USA 88:683-687.
19. Kubota, S., H. Siomi, T. Satoh, S. Endo, M. Maki, and M. Hatanaka. 1989. Functional similarity of HIV-I Rev and HTLV-I Rex proteins: identification of a new nucleolar-targeting signal in Rev protein. Biochem. Biophys. Res. Commun. 162:963-970.
20. Legiewicz, M., C. S. Badorrek, K. B. Turner, D. Fabris, T. E. Hamm, D. Rekosh, M. L. Hammarskjöld, and S. F. Le Grice. 2008. Resistance to RevM10 inhibition reflects a conformational switch in the HIV-1 Rev response element. Proc. Natl. Acad. Sci. USA 105:14365-14370.
21. Malim, M. H., J. Hauber, S. Y. Le, J. V. Maizel, and B. R. Cullen. 1989. The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 338:254-257.
22. Malim, M. H., D. F. McCarn, L. S. Tiley, and B. R. Cullen. 1991. Mutational definition of the human immunodeficiency virus type 1 Rev activation domain. J. Virol. 65:4248-4254.
23. Mann, D. A., I. Mikaélian, R. W. Zemmel, S. M. Green, A. D. Lowe, T. Kimura, M. Singh, P. J. Butler, M. J. Gait, and J. Karn. 1994. A molecular rheostat. Co-operative rev binding to stem I of the Rev-response element modulates human immunodeficiency virus type-1 late gene expression. J. Mol. Biol. 241:193-207.
24. Miller, M. D., and D. J. Hazuda. 2004. HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications. Drug Resist. Update 7:89-95.
25. Mills, N. L., M. D. Daugherty, A. D. Frankel, and R. K. Guy. 2006. An alpha-helical peptidomimetic inhibitor of the HIV-1 Rev-RRE interaction. J. Am. Chem. Soc. 128:3496-3497.
26. Mink, M., S. M. Mosier, S. Janumpalli, D. Davison, L. Jin, T. Melby, P. Sista, J. Erickson, D. Lambert, S. A. Stanfield-Oakley, M. Salgo, N. Cammack, T. Matthews, and M. L. Greenberg. 2005. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J. Virol. 79:12447-12454.
27. Nameki, D., E. Kodama, M. Ikeuchi, N. Mabuchi, A. Otaka, H. Tamamura, M. Ohno, N. Fujii, and M. Matsuoka. 2005. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions. J. Virol. 79:764-770.
28. Neumann, M., J. Harrison, M. Saltarelli, E. Hadziyannis, V. Erfle, B. K. Felber, and G. N. Pavlakis. 1994. Splicing variability in HIV type 1 revealed by quantitative RNA polymerase chain reaction. AIDS Res. Hum. Retrovir. 10:1531-1542.
29. Neville, M., F. Stutz, L. Lee, L. I. Davis, and M. Rosbash. 1997. The importin beta family member Crm1p bridges the interaction between Rev. and the nuclear pore complex during nuclear export. Curr. Biol. 7:767-775.
30. Perkins, A., A. W. Cochrane, S. M. Ruben, and C. A. Rosen. 1989. Structural and functional characterization of the human immunodeficiency virus Rev protein. J. Acquir. Immune Defic. Syndr. 2:256-263.
31. Pollard, V. W., and M. H. Malim. 1998. The HIV-1 Rev protein. Annu. Rev. Microbiol. 52:491-532.
32. Purcell, D. F., and M. A. Martin. 1993. Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J. Virol. 67:6365-6378.
33. Reeves, J. D., F. H. Lee, J. L. Miamidian, C. B. Jabara, M. M. Juntilla, and R. W. Doms. 2005. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J. Virol. 79:4991-4999.
34. Schwartz, S., B. K. Felber, D. M. Benko, E. M. Fenyo, and G. N. Pavlakis. 1990. Cloning and functional analysis of multiply spliced mRNA species of human immunodeficiency virus type 1. J. Virol. 64:2519-2529.
35. Svicher, V., T. Sing, M. M. Santoro, F. Forbici, F. Rodríguez-Barrios, A. Bertoli, N. Beerenwinkel, M. C. Bellocchi, F. Gago, A. d'Arminio Monforte, A. Antinori, T. Lengauer, F. Ceccherini-Silberstein, and C. F. Perno. 2006. Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. J. Virol. 80:7186-7198.
36. + cell count, despite virological failure. J. Infect. Dis. 197:1408-1418.
37. Swafford, K. L. 1999. PAUP 4.0: phylogenetic analysis with parsimony (and other methods), version 4.0b2a. Sinauer Associates Inc, Sunderland, MS.
38. Thomas, S. L., M. Oft, H. Jaksche, G. Casari, P. Heger, M. Dobrovnik, D. Bevec, and J. Hauber. 1998. Functional analysis of the human immunodeficiency virus type-1 Rev protein oligomerization interface. J. Virol. 72:2935-2944.
39. Wilke, C., R. Lenski, and C. Adami. 2003. Compensatory mutations cause excess of antagonistic epistasis in RNA secondary structure folding. BMC Evol. Biol. 3:3.
40. Zapp, M. L., and M. R. Green. 1989. Sequence-specific RNA binding by the HIV-1 Rev protein. Nature 342:714-716.
41. Zapp, M. L., T. J. Hope, T. G. Parslow, and M. R. Green. 1991. Oligomerization and RNA binding domains of the type 1 human immunodeficiency virus Rev protein: a dual function for an arginine-rich binding motif. Proc. Natl. Acad. Sci. USA 88:7734-7738.